	US 12,448,432 B2
	Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
Yihong Yao, Rockville, MD (US); Yanfeng Li, Hong Kong (CN); Yutian Wei, Hong Kong (CN); Shigui Zhu, Rockville, MD (US); Xin Yao, Rockville, MD (US); and Jiaqi Huang, Rockville, MD (US)
Assigned to AbelZeta Inc., Rockville, MD (US)
Filed by AbelZeta Inc., Rockville, MD (US)
Filed on Apr. 15, 2022, as Appl. No. 17/721,647.
Application 17/721,647 is a continuation of application No. 17/475,766, filed on Sep. 15, 2021, granted, now 11,439,665.
Application 17/475,766 is a continuation of application No. 16/877,069, filed on May 18, 2020, granted, now 11,207,349, issued on Dec. 28, 2021.
Claims priority of application No. 202010188038.1 (CN), filed on Mar. 17, 2020.
Prior Publication US 2022/0249568 A1, Aug. 11, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/47 (2006.01); A61K 35/17 (2025.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01)

CPC C07K 14/70596 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61K 40/4221 (2025.01); A61P 35/00 (2018.01); C12N 5/0636 (2013.01); A61K 2239/29 (2023.05)]

10 Claims

1. A nucleic acid encoding a bispecific chimeric antigen receptor (CAR), wherein the bispecific CAR comprises an amino acid sequence set forth in SEQ ID NO: 16, and wherein the bispecific CAR comprises an anti-CD20 antigen-binding region and an anti-CD19 antigen-binding region.